Adderall, a blend of amphetamine salts, follows three main routes out of your body: enzymatic breakdown in the liver, genetically variable processing by a key enzyme called CYP2D6, and pH-dependent excretion through the kidneys. Each of these pathways can speed up or slow down the drug’s effects, which is why two people on the same dose can have very different experiences. The interplay between liver chemistry, inherited enzyme profiles, and something as mundane as how acidic your urine is creates a surprisingly complex metabolic picture.
What the Liver Does to Adderall
After you swallow an Adderall tablet, it dissolves in your gut and gets absorbed into the bloodstream quickly and almost completely. Once it reaches the liver, the real metabolic work begins. The liver uses several enzyme-driven pathways to break amphetamine into smaller compounds the body can eliminate. One major route is oxidative deamination, which strips the amine group off the amphetamine molecule and converts it into inactive byproducts. Another is hydroxylation, where enzymes add an oxygen-containing group to produce compounds like 4-hydroxyamphetamine and norephedrine. A third pathway, oxidation, generates benzoic acid, which the body then converts to hippuric acid for excretion.
Among the liver enzymes involved, CYP2D6 plays a central role. This single enzyme is responsible for the hydroxylation step and is one of the primary determinants of how quickly your body clears amphetamine. But CYP2D6 is not the only player. Multiple enzymes participate, and the drug undergoes what pharmacologists call extensive metabolism, meaning a large fraction of each dose gets chemically altered before it ever leaves the body.
Not all of these pathways treat the two forms of amphetamine in Adderall equally. Some metabolic steps show a preference for the l-amphetamine isomer over the d-amphetamine isomer, a phenomenon called stereoselective metabolism. Because Adderall contains both isomers in a roughly 3:1 ratio of d- to l-amphetamine, this selectivity matters: the l-isomer tends to be cleared faster in certain pathways, which partly explains why d-amphetamine sticks around longer and contributes more to the drug’s clinical effects.1PubMed. The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder
How Your Genes Change the Equation
CYP2D6 is one of the most genetically variable enzymes in the human body. The gene encoding it has over a hundred known variants, and those variants can produce enzymes that work at very different speeds. Some people inherit versions that produce a fully functional enzyme, some inherit versions that produce an enzyme with reduced activity, and some inherit versions that produce no working enzyme at all. On the other end, a small percentage of people carry extra copies of the gene, producing unusually high amounts of the enzyme. This genetic diversity splits the population into metabolizer groups that range from poor (very slow clearance) to ultrarapid (very fast clearance).
For someone who is a poor metabolizer, amphetamine lingers in the bloodstream longer, which can intensify side effects at a standard dose. For an ultrarapid metabolizer, the drug may be broken down so quickly that a typical dose feels underwhelming. CYP2D6 handles roughly a fifth to a quarter of all prescription drugs, so this variability has consequences far beyond Adderall, but it is especially relevant here because CYP2D6 is a primary route of amphetamine hydroxylation.2PubMed Central. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine
Complicating things further, your genetic metabolizer status is not necessarily your functional metabolizer status. Certain medications can inhibit CYP2D6 so powerfully that a person who genetically qualifies as a normal metabolizer effectively becomes a poor metabolizer while taking those drugs. This is called phenoconversion, and it is one of the least appreciated sources of unexpected drug responses. If your doctor has you on a CYP2D6 inhibitor and Adderall at the same time, the interaction can meaningfully change how long the amphetamine stays active in your system.2PubMed Central. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine
The Urinary pH Factor
Once amphetamine has passed through the liver, a substantial fraction ends up in the kidneys for excretion. Here, the chemistry of your urine determines how much of the drug gets reabsorbed back into the bloodstream versus how much gets flushed out. Amphetamine is a weak base, and in acidic urine it becomes ionized, a charged state that prevents it from slipping back through the walls of the kidney tubules. In alkaline urine, more of the drug remains non-ionized and gets passively reabsorbed, returning to circulation and prolonging its effects.
This is not a subtle effect. Shifting urine pH from alkaline to acidic can dramatically change how much amphetamine appears in the urine and how quickly blood levels fall. Research on this relationship has shown that amphetamine excretion increases as urine pH drops and urine flow increases.3Journal of Analytical Toxicology. Urinary Excretion of d-Amphetamine Following Oral Doses in Humans: Implications for Urine Drug Testing Physiologically based pharmacokinetic modeling has confirmed that when urine pH is altered, tubular ionization, passive reabsorption, renal clearance, and systemic drug exposure all shift in concert.4PubMed Central. Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine
In practical terms, this means that anything influencing your urine acidity can influence how long Adderall works. A diet heavy in citrus fruits, cranberry juice, or vitamin C supplements tends to acidify urine, potentially shortening the drug’s duration of action. Conversely, a diet high in certain vegetables, dairy, or antacids like sodium bicarbonate can push urine toward alkaline, potentially prolonging it. Adderall’s prescribing information acknowledges this relationship, and clinicians who are aware of it sometimes consider dietary habits when patients report unexpectedly short or long duration of effect.
Everyday Factors That Shift Urine pH
Most people do not think about the acidity of their urine, but it fluctuates throughout the day based on several factors. The most direct one is diet. Protein-rich meals, especially those heavy in meat, tend to produce more acidic urine. Plant-based meals tend to push urine toward the alkaline side. Hydration status matters too: dehydration generally concentrates urine and can shift pH, while drinking large volumes of water increases urine flow, which independently increases the rate of amphetamine excretion regardless of pH.
Medications add another layer. Proton pump inhibitors used for acid reflux, potassium citrate prescribed for kidney stones, and simple over-the-counter antacids can all alkalinize urine. On the acidifying side, methenamine (used for urinary tract infections) and high-dose vitamin C are common culprits. If you start or stop any of these while taking Adderall, the effective duration of your stimulant dose may shift without any change to the prescription itself.
Certain medical conditions also alter urine pH chronically. Kidney tubular disorders, chronic urinary infections, and metabolic conditions like diabetic ketoacidosis all create sustained pH changes that can meaningfully affect amphetamine clearance. For people with these conditions, Adderall dosing may require closer monitoring than usual.
Drug Interactions That Affect Metabolism
Beyond urine pH, the most clinically relevant interactions involve drugs that compete for or inhibit CYP2D6, the liver enzyme we discussed earlier. One well-studied example is fluoxetine (Prozac), a widely prescribed antidepressant and a potent CYP2D6 inhibitor. Research in animal models has shown that fluoxetine treatment leads to higher concentrations of amphetamine in the central nervous system and potentiates both the locomotor and dopamine-releasing effects of the drug. The mechanism appears to be straightforward: fluoxetine slows the hepatic metabolism of amphetamine by blocking CYP2D6 activity.5PubMed. Acute fluoxetine treatment potentiates amphetamine hyperactivity and amphetamine-induced nucleus accumbens dopamine release: possible pharmacokinetic interaction
Fluoxetine is far from the only CYP2D6 inhibitor a patient might encounter. Paroxetine, bupropion, quinidine, and certain antihistamines all inhibit the enzyme to varying degrees. Because many people prescribed Adderall for ADHD also take antidepressants or other psychiatric medications, these pharmacokinetic overlaps are common in clinical practice. The practical effect is that adding a CYP2D6 inhibitor can mimic the experience of a dose increase on Adderall, sometimes producing side effects like elevated heart rate, insomnia, or anxiety that were not present before the second medication was introduced.
Interestingly, a comprehensive pharmacokinetic review of amphetamines noted that beyond drug-induced changes in urinary pH, there are actually few well-documented pharmacokinetic interactions of clinical significance for amphetamine.1PubMed. The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder That does not mean CYP2D6 inhibition is trivial. It means that most of the dramatic shifts in amphetamine exposure come from urine pH changes rather than liver-enzyme competition, and that the interaction profile is narrower than many people assume.
Why Children Process Adderall Faster Than Adults
Age has a measurable impact on amphetamine pharmacokinetics. In replicated studies, children show a plasma half-life of roughly seven hours, compared to about ten to twelve hours in adults.1PubMed. The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder That means a child’s body clears the drug substantially faster, which is one reason pediatric dosing schedules often involve more frequent administration or extended-release formulations to maintain coverage through a school day.
Body weight is a fundamental determinant of observed plasma concentrations. A 30-kilogram child and a 90-kilogram adult given the same milligram dose will reach very different blood levels. But the difference is not just about dilution in a larger body. Children tend to have proportionally larger livers relative to body weight and higher rates of hepatic blood flow, which accelerates first-pass metabolism. Their kidneys also tend to filter more efficiently relative to body size. Both factors contribute to the shorter half-life observed in pediatric populations.
On the other end of the age spectrum, older adults often have reduced liver and kidney function, which can slow clearance and raise the effective potency of a given dose. Formal pharmacokinetic studies of amphetamines in elderly populations are limited, but the general pharmacological principle applies: as hepatic and renal capacity declines with age, drugs that rely on those organs for elimination tend to accumulate more readily.
Lisdexamfetamine and a Completely Different Metabolic Starting Point
Lisdexamfetamine (sold as Vyvanse) is worth understanding alongside Adderall because it illustrates just how much the metabolic pathway matters. Lisdexamfetamine is a prodrug, meaning it is pharmacologically inactive as swallowed. It only becomes active d-amphetamine after the body cleaves off a lysine amino acid that is chemically bonded to the amphetamine molecule. This cleavage does not happen in the liver. It happens primarily inside red blood cells, where peptidase enzymes in the cytosol break the bond.6Neuropsychiatric Disease and Treatment. Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells
Because activation depends on a rate-limited enzymatic step in red blood cells rather than on gastric absorption speed, lisdexamfetamine produces a smoother rise in d-amphetamine blood levels than immediate-release Adderall. The design also makes it harder to abuse by snorting or injecting, since those routes bypass the gut but still require the same enzymatic conversion. From a metabolism standpoint, the key difference is that CYP2D6 variability and urine pH still affect the clearance of the resulting d-amphetamine, but the initial activation step is governed by an entirely separate set of enzymes. So the genetic lottery that determines your CYP2D6 status does not influence how quickly you convert lisdexamfetamine to its active form, only how quickly you clear it afterward.
Detection Windows and the Role of pH
For anyone facing a drug test, the pH effect on amphetamine excretion takes on a very practical dimension. Standard urine immunoassay tests detect amphetamine and its metabolites above a threshold concentration. How long amphetamine stays detectable in urine depends heavily on how acidic or alkaline the urine is during the elimination window. Under acidic conditions, excretion is rapid and the detection window is shorter. Under alkaline conditions, more drug is reabsorbed back into the body, less appears in the urine at any given time, and the window can be extended because the drug is being released more slowly over a longer period.3Journal of Analytical Toxicology. Urinary Excretion of d-Amphetamine Following Oral Doses in Humans: Implications for Urine Drug Testing
This means that two people taking the same dose of Adderall, one with naturally acidic urine and one with naturally alkaline urine, can produce very different test results at the same time point after their last dose. Urine flow rate adds another variable: someone who is well-hydrated and producing large volumes of urine will excrete amphetamine faster than someone who is dehydrated. For forensic and workplace testing programs, this biological variability is a recognized complication, and it is one reason that confirmatory testing with mass spectrometry uses specific concentration cutoffs rather than a simple positive-or-negative approach.
CYP2D6 Phenotyping and the Limits of Genetic Testing
Pharmacogenomic testing for CYP2D6 has become increasingly accessible, with commercial services offering genotype panels that assign you to a metabolizer category. In principle, this information could guide Adderall dosing. In practice, the picture is messier. The CYP2D6 gene is unusually difficult to genotype accurately because it has structural variants, gene deletions, gene duplications, and hybrid genes formed by recombination with a nearby pseudogene. Not all commercial panels test for all known variants, so a result labeled “normal metabolizer” might miss a rare allele that actually reduces function.
Even when genotyping is accurate, phenoconversion complicates interpretation. If you carry normal-metabolizer alleles but take a potent CYP2D6 inhibitor, your functional status is closer to a poor metabolizer, and no genetic test will flag that. Some researchers have proposed measuring actual enzyme activity through probe drugs rather than relying on genotype alone, but this approach is not widely used in clinical settings. For now, CYP2D6 genotyping provides useful directional information, especially at the extremes of poor and ultrarapid metabolism, but it is not a precise dial that tells your doctor exactly how you will respond to Adderall.
The variability in CYP2D6 activity is also not evenly distributed across populations. Certain alleles that reduce or eliminate enzyme function are more common in specific ethnic and geographic groups, while gene duplications leading to ultrarapid metabolism are more prevalent in others. This population-level variation means that standard dosing guidelines, which are generally calibrated for an average metabolizer, may systematically over- or under-dose certain groups. It is one of the areas where personalized medicine has the clearest potential to improve outcomes, even if implementation is still catching up to the science.2PubMed Central. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine
When Metabolism Feels Off but the Dose Has Not Changed
A common frustration among long-term Adderall users is the sense that the medication “stops working” or changes in effectiveness without any change in prescription. While pharmacodynamic tolerance, where the brain adapts to the drug’s effects on dopamine signaling, is often the primary explanation, metabolic shifts can also contribute. Starting a new medication that inhibits CYP2D6, changing your diet substantially, developing a kidney condition that alters urine pH, or even seasonal changes in hydration habits can all shift how much active amphetamine reaches your brain from the same pill.
Clinicians who are aware of these metabolic variables can sometimes resolve the issue without increasing the dose. Reviewing the full medication list for CYP2D6 interactions, asking about dietary changes or new supplements, and checking kidney function can all uncover a metabolic explanation for what feels like tolerance. It is a less common clinical reflex than simply adjusting the dose, but it is a more precise one, and it avoids the escalation cycle that patients and providers both worry about with controlled substances.